Skip to search formSkip to main contentSkip to account menu

asfotase alfa

Known as: Asfotase alpha 
National Institutes of Health

Related topics

Related topics

6 relations
0.8 ML asfotase alfa 100 MG/ML Injection [Strensiq]

Broader (3)

Alkaline PhosphataseImmunoglobulin GRecombinant Fusion Proteins

Narrower (2)

ENB-0040Strensiq

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Hearing impairment improved after treatment with asfotase alfa in a case of perinatal hypophosphatasia
2019
2019
Ectopic Ocular Surface Calcification in Patients With Hypophosphatasia Treated With Asfotase Alfa.
PURPOSE To assess for ectopic ocular calcification in a series of patients with hypophosphatasia (HPP) treated with asfotase alfa… 
2019
2019
Findings of amplitude-integrated electroencephalogram recordings and serum vitamin B6 metabolites in perinatal lethal hypophosphatasia during enzyme replacement therapy
2019
2019
No vascular calcification on cardiac computed tomography spanning asfotase alfa treatment for an elderly woman with hypophosphatasia.
2018
2018
Reappearance of hypomineralized bone after discontinuation of asfotase alfa treatment for severe childhood hypophosphatasia
2018
2018
Enzyme Replacement Therapy in Hypophosphatasia
Hypophosphatasia (HPP) is associated with significant morbidity and mortality in pediatric patients. The disease also imposes a… 
2018
2018
A Case of the Perinatal Form Hypophosphatasia Caused by a Novel Large Duplication of the ALPL Gene and Report of One Year Follow-up with Enzyme Replacement Therapy
Hypophosphatasia (HPP) is a rare disease caused by mutations in the ALPL gene encoding tissue-non-specific isoenzyme of alkaline… 
Review
2017
Review
2017
Asfotase alfa treatment of an African-American infant with perinatal hypophosphatasia and homozygous hemoglobin SC disease
Hypophosphatasia (HPP, OMIM #241500) is characterized by defective bone mineralization, associated with decreased activity of the… 
2015
2015
Significantly improved muscle strength, running speed, and agility in children with hypophosphatasia treated with asfotase alfa
2014
2014
Sustained efficacy and tolerability in infants and young children with life-threatening hypophosphatasia treated with asfotase alfa
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)